# Pizarra — PT-pseudo_4bfd4ec864d8 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4bfd4ec864d8
Task: 1

Encounter: Urology - outpatient on 02 Mar 2025.
Referrer: Dr. H. Martens (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 72-year-old male
  - PSA: 11.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.35 ng/mL²
  - PSA velocity: 1.56 ng/mL/yr
  - Prior PSA: 8.3 ng/mL
  - Prostate volume: 31.6 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.833 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NSAIDs
  - Additional notes: PSA 11 ng/mL. PI-RADS 5. PSAD 0.35. Prostate volume 32 mL. DRE nodus. csPCa 0.83.

Vitals: weight 82 kg, height 183 cm, BMI 24.5, BP 118/75 mmHg, HR 66 bpm. Smoking: Non-smoker.

Chief complaint: Current evaluation addresses sustained PSA elevation alongside a newly identified PI-RADS 5 lesion on recent imaging.

History: The patient, a 72-year-old retired plumber, entered urological monitoring after an initial PSA rise in early 2022. He identifies as a non-smoker and currently resides in a ground-floor apartment with his partner, having been widowed. Respiratory management involves tiotropium alongside PRN salbutamol for his COPD. Urinary symptom burden remains low (IPSS 6), characterized mainly by sporadic nocturia, with explicit denial of haematuria or pelvic discomfort. Recreational gardening continues, and he recently finished six physiotherapy visits addressing chronic lower back ache unrelated to prostate pathology. Daily activity features regular neighbourhood walks. Notably, he reports no unexplained weight reduction, skeletal pain, or systemic complaints.

Physical examination: DRE — texture: asymmetrically enlarged gland; mobility: fixed; asymmetry: firm, discrete nodule localized to the right peripheral zone. Abdominal and cardiovascular assessments remain entirely unremarkable. Blood pressure is stable, and cardiac rhythm registers at 66 bpm.

Patient info: retired plumber; Widowed; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Gardening, no structured exercise; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Radiology — chest X-ray (routine); Audiology — hearing test; Physiotherapy — lower back, six sessions.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.60 +/- 0.20   (95% CI 0.20-0.93)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 5.9 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=1.0, psa=11.0, age=72.0, psad=0.35, dre_ord=1.0, vol=31.6, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the visible panel data (PI-RADS=5, PSA=11.0, Age=72, PSA Density=0.35, DRE=Nodus, Volume=31.6 mL, Prior Biopsy=Negative) and failed to incorporate the PSA velocity (1.56 ng/mL/yr) or the specific context of the guideline criterion (prior negative biopsy).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a 60% probability, which is highly uncertain ($\pm 0.20$). This wide interval means the classifier cannot distinguish between the clinical scenarios. Specifically, the prior fails to account for the guideline's emphasis on the prior negative biopsy status, which is a critical factor in determining the need for re-biopsy. Furthermore, the prior does not weigh the high csPCa probability (0.833) against the DRE finding of a nodule, which could be misinterpreted as benign.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the initial PSA rise in 2022
laboratory panel - full panel
family-history of prostate cancer (anamnesis)

GUIDELINE ANCHOR
The guideline criterion mandates a repeat biopsy when an mpMRI shows a PI-RADS 4-5 lesion, and it constrains the decision by stating that a stable MRI (PI-RADS 1-3) does not make repeat biopsy superfluous.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_4bfd4ec864d8", "radiology_report": "PI-RADS 5 lesion in the right mid-peripheral zone. Prostate volume 31.6 mL; PSA density 0.35 ng/mL/mL. csPCa predicted probability 0.833."}
get_psa_trend
{"case_id": "PT-pseudo_4bfd4ec864d8", "psa_trend": [{"date": "Mar 2022", "val": 4.2}, {"date": "Dec 2022", "val": 5.3}, {"date": "Sep 2023", "val": 6.8}, {"date": "Jun 2024", "val": 8.6}, {"date": "Mar 2025", "val": 11.0}]}
get_previous_notes
{"case_id": "PT-pseudo_4bfd4ec864d8", "previous_notes": [{"date": "13 Mar 2023", "author": "Dr. H. Martens (GP)", "text": "Clinical review on 13 March 2023 addressed a PSA increase to 6.3 ng/mL. Subsequent multiparametric MRI and systematic core biopsy yielded negative results for malignancy, with the encounter logged for ongoing urological monitoring."}]}
get_lab_results
{"case_id": "PT-pseudo_4bfd4ec864d8", "laboratory_results": [{"name": "PSA", "val": "11.0 ng/mL", "date": "10 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.62 ng/mL", "date": "10 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "15%", "date": "10 Feb 2025", "flag": "L"}]}
NOT RETRIEVED
get_family_history
Family history of prostate cancer anamnesis was not retrieved, which is not critical for the immediate decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling Now:
- mpMRI report: PI-RADS 5 lesion in the right mid-peripheral zone.
- PSA trend: Rising trajectory from 4.2 ng/mL (Mar 2022) to 11.0 ng/mL (Mar 2025), with a velocity of 1.56 ng/mL/yr (calculated from trend data).
- Guideline criterion: Re-biopsy is indicated for a PI-RADS 4-5 lesion following a prior negative biopsy.

AGAINST Sampling Now:
- Previous notes: Prior biopsy was negative.
- Lab results: Free PSA is 1.62 ng/mL (15%), which is borderline but not explicitly used as a contraindication here.

WHERE THIS LEANS
The evidence strongly supports proceeding with a targeted biopsy based on the PI-RADS 5 finding and the established guideline criterion for re-biopsy after a negative prior biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

No frozen image embeddings are on file for this patient, so the image-embedding head could not be run. This contributes NO evidence in either direction — do not read the absence of a score as reassurance.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is strongly supported by the guideline criterion for re-biopsy when a PI-RADS 5 lesion is identified following a prior negative biopsy. This is driven by the PI-RADS 5 score and the prior negative biopsy status. The PSA trend, rising from 4.2 ng/mL to 11.0 ng/mL, further supports the need for further investigation. The evidence converges on proceeding with a targeted biopsy.

Variables that carried weight: bx=decisive, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
